pyridoxamine has been researched along with Cardiac Hypertrophy in 1 studies
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, KC | 1 |
| Liang, JT | 1 |
| Tsai, PS | 1 |
| Wu, MS | 1 |
| Hsu, KL | 1 |
1 other study available for pyridoxamine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen.
Topics: Animals; Aorta; Arteries; Cardiac Output; Cardiomegaly; Collagen; Diabetes Mellitus, Experimental; G | 2009 |